Baraliakos, Xenofon http://orcid.org/0000-0002-9475-9362
Szumski, Annette E.
Kwok, Kenneth K.
Vlahos, Bonnie
Borlenghi, Cecilia E.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies
https://doi.org/10.1007/s40744-024-00656-3
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies
https://doi.org/10.1007/s40744-024-00656-3
Documents that mention this clinical trial
Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies
https://doi.org/10.1007/s40744-024-00656-3
Documents that mention this clinical trial
Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies
https://doi.org/10.1007/s40744-024-00656-3
Documents that mention this clinical trial
Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies
https://doi.org/10.1007/s40744-024-00656-3
Funding for this research was provided by:
Pfizer
Article History
Received: 17 November 2023
Accepted: 14 February 2024
First Online: 15 March 2024
Declarations
:
: X. Baraliakos: Research Support: AbbVie, Novartis, MSD; Consultant, Speakers Bureau, Scientific Advisory Board, and Honoraria: AbbVie, Amgen, BMS, Chugai, Galapagos, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, UCB; A.E. Szumski: was an employee of Syneos Health and was contracted by Pfizer to provide statistical support for the development of this paper; K.K. Kwok, B. Vlahos, C.E. Borlenghi: employees of Pfizer and hold stock in Pfizer.
: The final protocol, any amendments, and informed consent were reviewed and approved by the institutional review boards or institutional ethics committees at each of the investigational centers participating in the study. Details of the ethics committees are available upon request. All patients provided written informed consent for participation in the study. This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonisation Good Clinical Practice Guidelines.